Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
In
Investing.comBy Investing.com10/23/2026, 4:14:34 PM
EXECUTIVE SUMMARY
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results....
Key Takeaways
- Genmab stock surges 9% following positive phase 3 ovarian cancer trial results.
Read Complete Original Article
Published originally on Investing.com
Related News
finance11 minutes ago
Aim ImmunoTech CEO Equels buys $5,093 of common stock
Aim ImmunoTech CEO Equels buys $5,093 of common stock....
finance16 minutes ago
OptionMetrics flags hidden gems in commodities as wheat, soybeans outshine copper
OptionMetrics flags hidden gems in commodities as wheat, soybeans outshine copper....
finance18 minutes ago
Earnings call transcript: First Western Financial tops profit trend in Q3 2026
Earnings call transcript: First Western Financial tops profit trend in Q3 2026....
finance24 minutes ago
Popular declares $0.90 quarterly dividend per share
Popular declares $0.90 quarterly dividend per share....
Multikhabar App
All Information In One Place
Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!